Lantheus (LNTH) Expected to Announce Quarterly Earnings on Wednesday

Lantheus (NASDAQ:LNTH - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect Lantheus to post earnings of $1.64 per share and revenue of $377.37 million for the quarter.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. On average, analysts expect Lantheus to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Lantheus Trading Down 1.8 %

Shares of LNTH traded down $1.87 during trading hours on Friday, reaching $101.77. 644,509 shares of the stock traded hands, compared to its average volume of 955,167. Lantheus has a 52-week low of $65.76 and a 52-week high of $126.89. The company has a market cap of $6.97 billion, a P/E ratio of 16.93 and a beta of 0.20. The company's 50-day moving average price is $97.37 and its two-hundred day moving average price is $95.23.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LNTH. Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. B. Riley lowered their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 63,109 shares of company stock valued at $6,016,046. Insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.